Dr. Samer K. Khaled, MD

Dr. Khaled practices at Arnold Palmer Hospital for Children in Orlando, Florida.

Dr. Khaled's NPI, 1376785006, was assigned on March 26, 2009. Dr. Khaled graduated from Cairo University School of Medicine in 1998. Dr. Khaled holds Florida license ME93692.

Dr. Khaled's primary practice is Arnold Palmer Hospital for Children, at 92 W Miller St, Orlando, FL 32806 in Orange County. The practice phone is (407) 650-5028.

Dr. Khaled's primary practice is Arnold Palmer Hospital for Children in Orlando, Florida. Dr. Khaled is also affiliated with Orlando Regional Medical Center. The medical group on file is Orlando Health Medical Group. Dmand AI also links Dr. Khaled to 1 more hospital, 2 medical groups and 1 other site, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Khaled practices, 3 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Khaled's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Khaled is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Khaled's licenses on file in 3 states: Florida, California and New York.

CMS data shows 196 Medicare services from Dr. Khaled across 1 procedure code in 2024, for 31 Medicare patients. Medicare paid $12,050 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 31 Medicare patients who saw Dr. Khaled in 2024. 75% of them have high blood pressure, and 75% have high cholesterol. Their average risk score is 3.62, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Khaled's median patient age at 69, with 49% women.

In 2024, Dr. Khaled wrote 18 Medicare Part D claims. Every claim was for a generic drug. CMS names the drug for 17 of them, across 1 drug with 11 or more claims each, at $322 in total drug cost. In 2018, CMS named 11 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 80 out of 100 for Dr. Khaled for performance year 2024, reported as part of a group. Dr. Khaled accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 54 papers to Dr. Khaled, published from 2012 to 2023. 2019 was the busiest year, with 9. The most frequent topics are Hematopoietic Stem Cell Transplantation, Leukemia, Myeloid, Acute and Precursor Cell Lymphoblastic Leukemia-Lymphoma. Dr. Khaled has published most often in Biol Blood Marrow Transplant. Dr. Khaled's most frequent co-authors are Guido Marcucci, MD, Ryotaro Nakamura, MD and Stephen J. Forman, MD.

Dmand AI links Dr. Khaled to 14 clinical trials, 6 of them phase 2 studies. 5 are still active or recruiting. Conditions studied include Leukemia, Myeloid, Acute, Myelodysplastic Syndromes and Leukemia, Myeloid. City of Hope Medical Center sponsors the most, 2. Open Payments lists research payments to Dr. Khaled that name 1 trial.

CMS Open Payments shows 225 general payments to Dr. Khaled from 16 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 34% of the total. Alexion Pharmaceuticals, Inc. paid the most, $67,452. It also lists 139 research payments totaling $60,820 in 2016, naming 1 clinical trial.

Dr. Khaled graduated from Cairo University School of Medicine in 1998.

Dr. Khaled is in network with 16 carriers, including United Healthcare, Blue Cross Blue Shield of Michigan and Cigna. PPO plans come from the most carriers, 11. Check the plan with the practice before a visit.